GOLDEN STATE MEDICAL SUPPLY, INC. v. AUSTARPHARMA LLC

CourtDistrict Court, D. New Jersey
DecidedJune 30, 2022
Docket2:21-cv-17137
StatusUnknown

This text of GOLDEN STATE MEDICAL SUPPLY, INC. v. AUSTARPHARMA LLC (GOLDEN STATE MEDICAL SUPPLY, INC. v. AUSTARPHARMA LLC) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GOLDEN STATE MEDICAL SUPPLY, INC. v. AUSTARPHARMA LLC, (D.N.J. 2022).

Opinion

NOT FOR PUBLICATION UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

GOLDEN STATE MEDICAL SUPPLY INC.,

Plaintiff, Civil Action No. 21-17137 v. OPINION AUSTARPHARMA LLC, et al.,

Defendants.

ARLEO, UNITED STATES DISTRICT JUDGE THIS MATTER comes before the Court on Defendants AustarPharma LLC’s (“AP LLC”), AustarPharma Research, LLC’s (“AP Research”), AustarPharma Laboratories, LLC’s (“AP Labs”), and Rong Liu’s (“Liu” and together with AP LLC, AP Research, and AP Labs, the “AP Defendants”) Motion to Dismiss pursuant to Federal Rules of Civil Procedure 12(b)(5) and 12(b)(6) and to Strike pursuant Federal Rule of Civil Procedure 12(f), ECF No. 29. Plaintiff Golden State Medical Supply Inc. (“GSMS” or “Plaintiff”) opposes the Motion. ECF No. 35. For the reasons explained below, the Motion is GRANTED in part and DENIED in part. I. FACTUAL BACKGROUND1 This action arises out of a deteriorating business relationship between AP LLC, a generic pharmaceutical manufacturer, and Plaintiff, a distributor. See generally Compl.

1 These facts are drawn from the Complaint, ECF No. 1, documents integral to or relied upon by the Complaint, and the public record. See In re Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997). 1 Plaintiff and AP LLC were parties to a Product Supply Agreement dated February 19, 2014, which provided that Plaintiff would periodically order, and AP LLC would timely deliver, stocks of certain drugs referred to in the Complaint as “Product M” and “Product S.”2 Id. ¶¶ 79- 80; see also Certification of Paul H. Aloe (“Aloe Cert.”) Ex. A (the “First Supply Agreement”), ECF No. 29.2.3 Plaintiff, in turn, contracted to resell the drugs received from AP LLC to

purchasers including the United States Government. Id. ¶¶ 86, 99. On September 23, 2019, the Government contacted Plaintiff to renegotiate the price at which it purchased Product S from Plaintiff. Id. ¶ 104. Plaintiff thereafter advised AP LLC that it could not resell its on-hand inventory of Product S that it had purchased from AP LLC in 2019 “due to the pricing in the Government market having dropped dramatically and unexpectedly.” Aloe Cert. Ex. B, at 1, ECF No. 29.3. Plaintiff requested a price reduction for Product S tablets from AP LLC, including a “shelf stock adjustment for all on hand inventory of [Product S] Tablets at GSMS.” Id. AP LLC and Plaintiff subsequently entered into two letter agreements on March 6, 2020,

wherein AP LLC agreed to provide a credit memo to GSMS in the amount of $3,819.053.37, representing a discount for Plaintiff’s on-hand inventory of Product S (the “Purchase Credit”). Id. ¶¶ 108-09; see also Aloe Cert. Exs. B-D (the “Credit Agreements”). Under the terms of the Credit Agreements, AP LLC would offset future invoices issued to Plaintiff with the Purchase Credit in installments, based on sales and an agreed upon credit usage schedule, until the Purchase Credit was fully recouped. Aloe Cert. Ex. B, at 1. The Credit Agreements projected a “full recoupment”

2 “Product S” was added to the supply agreement in June 2019. Compl. ¶ 97. 3 The First Supply Agreement, as well as the other agreements between the parties discussed below, are expressly relied upon by the Complaint and may be considered on a motion to dismiss. 2 of the Purchase Credit by September 2021 but provided that a variety of factors could impact this timeline. Id. The parties further agreed to meet in September 2020 and May 2021 to “conduct a business review” and “to use best efforts to adjust the credit schedule, as necessary, in a good faith effort to timely complete full recoupment of the [Purchase] Credit.” Aloe Cert. Ex. D. On May

5, 2020, Plaintiff and AP LLC entered into a new Supply Agreement, which specifically incorporated the terms of the Credit Agreements. Compl. ¶ 113; see also Aloe Cert. Ex. E (the “Second Supply Agreement”, and together with the First Supply Agreement, the “Supply Agreements”). The Complaint alleges that since 2019, AP LLC has consistently breached its obligations to supply Products M and S in full and on time, which has rendered Plaintiff unable to satisfy its obligations to resell the drugs to its customers. See, e.g., Compl. ¶¶ 81-84, 98, 111. At the same time, AP LLC allegedly sold Products M and S to third parties, including a direct competitor of GSMS, instead of fulfilling its obligations under the Supply Agreements. Id. ¶¶ 127-28. The Complaint further alleges that regulations governing Plaintiff’s government re-sale contracts made

it difficult for Plaintiff to switch to a new provider of Products M and S, a fact which AP LLC used to “stranglehold[] GSMS into continuing to do business with [it].” Id. ¶ 88. From November 2020 to March 2021, the parties held four meetings “over interstate wire communications” to discuss Plaintiff’s grievances concerning the Supply Agreements and Purchase Credit. First, on November 10, 2020, Plaintiff told AP LLC that it was not complying with the Supply Agreements, and AP LLC “told [Plaintiff] that it would try to produce Product S per the contracts.” Id. ¶ 113. Second, on November 24, 2020, AP LLC told Plaintiff “that it would investigate how to make sales of other products to other non-GSMS customers to pay” the Purchase Credit, while Liu “promised to secure bank loans or other notes to pay [Plaintiff] back.” 3 Id. ¶ 114. Third, on December 8, 2020, Plaintiff requested AP LLC’s audited financial statements, but AP LLC “hesitated on committing to provide” the statements. Id. Fourth, on March 30, 2021, Liu cited the COVID-19 pandemic as a basis for AP LLC’s supply problems and stated that AP LLC was not being sued by a third party. Id. ¶ 117. AP LLC also stated that “it was running extra

shifts on weekdays and weekends to catch up.” Id. Plaintiff generally alleges that some of the statements made by AP LLC and Liu during the aforementioned meetings were false and intended to “dupe GSMS into accepting new delivery schedules of Product S,” induce Plaintiff into submitting new orders, and “forestall payment” of the Purchase Credit, all while AP LLC knew it could not produce or timely deliver the products. See, e.g., id. ¶¶ 113, 126. Finally, Plaintiff asserts that AP LLC and Liu acted in concert with the other Defendants: AP Labs, AP Research, Austar International Limited (“AIL”), and Bostal Drug Delivery Co., Ltd. (“Bostal”4 and together with AIL and the AP Defendants, “Defendants”).5 See, e.g., id. ¶ 124. As alleged in the Complaint, Liu is the majority owner of AP LLC and owns Bostal, AP Research, and AP Labs, while AIL has a minority stake in AP LLC. Id. ¶¶ 25-26, 124. Plaintiff alleges that

during the period that AP LLC was breaching its obligations to Plaintiff, AIL filed a lawsuit against Liu, AP LLC, and Bostal asserting various derivative and direct claims arising from allegations that Liu misappropriated AP LLC’s assets and operated Bostal as a competing company in China (the “AIL v. AP Action”). Id. ¶ 27; see also Austar Int’l Ltd. v. AustarPharma LLC, 425 F. Supp. 3d 336 (D.N.J. 2019). Though the AIL v. AP Action concerns a now-settled internal corporate

4 The Complaint names Bostal and Guangzhou Bristol Drug Delivery Co., Ltd. (“Bristol”) as two distinct parties in the caption but later explains that the entity previously named “Guangzhou Bristol Drug Delivery Co., Ltd.” was renamed “Bostal Drug Delivery Co., Ltd.” Compl. ¶ 10. The Court therefore understands Bristol and Bostal to be the same entity. 5 Plaintiff also initially named LSQ Funding Group L.C. (“LSQ”) as a defendant.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

H. J. Inc. v. Northwestern Bell Telephone Co.
492 U.S. 229 (Supreme Court, 1989)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Bridge v. Phoenix Bond & Indemnity Co.
553 U.S. 639 (Supreme Court, 2008)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
In Re Insurance Brokerage Antitrust Litigation
618 F.3d 300 (Third Circuit, 2010)
Sanchez v. Triple-S Management, Corp.
492 F.3d 1 (First Circuit, 2007)
United States v. Paul Bergrin
650 F.3d 257 (Third Circuit, 2011)
Karen McPeters v. Frederick Edwards
464 F. App'x 351 (Fifth Circuit, 2012)
United States v. Eugene Hannigan
27 F.3d 890 (Third Circuit, 1994)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Frederico v. Home Depot
507 F.3d 188 (Third Circuit, 2007)
Seidenberg v. Summit Bank
791 A.2d 1068 (New Jersey Superior Court App Division, 2002)
Maniscalco v. Brother International Corp.
627 F. Supp. 2d 494 (D. New Jersey, 2009)
Wade v. Kessler Institute
798 A.2d 1251 (Supreme Court of New Jersey, 2002)
Banco Popular North America v. Gandi
876 A.2d 253 (Supreme Court of New Jersey, 2005)
District 1199P Health & Welfare Plan v. Janssen, L.P.
784 F. Supp. 2d 508 (D. New Jersey, 2011)
McPeters v. Edwards
806 F. Supp. 2d 978 (S.D. Texas, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
GOLDEN STATE MEDICAL SUPPLY, INC. v. AUSTARPHARMA LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/golden-state-medical-supply-inc-v-austarpharma-llc-njd-2022.